{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T07:10:27Z","timestamp":1742713827646,"version":"3.40.2"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T00:00:00Z","timestamp":1714176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100009576","name":"Nantong Municipal Commission of Health and Family Planning","doi-asserted-by":"publisher","award":["MA2021030"],"award-info":[{"award-number":["MA2021030"]}],"id":[{"id":"10.13039\/501100009576","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biotechnol"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12033-024-01143-4","type":"journal-article","created":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T12:01:42Z","timestamp":1714219302000},"page":"1584-1596","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Up-Regulation of MELK Promotes Cell Growth and Invasion by Accelerating G1\/S Transition and Indicates Poor Prognosis in Lung Adenocarcinoma"],"prefix":"10.1007","volume":"67","author":[{"given":"Qinggan","family":"Ni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqing","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongbo","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5621-7450","authenticated-orcid":false,"given":"Guanglin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weirong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,27]]},"reference":[{"issue":"6","key":"1143_CR1","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 68(6), 394\u2013424.","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"11","key":"1143_CR2","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1002\/ijc.29915","volume":"138","author":"J Minguet","year":"2016","unstructured":"Minguet, J., Smith, K. H., & Bramlage, P. (2016). Targeted therapies for treatment of non-small cell lung cancer: Recent advances and future perspectives. International Journal of Cancer, 138(11), 2549\u20132561.","journal-title":"International Journal of Cancer"},{"issue":"suppl4","key":"1143_CR3","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/annonc\/mdx222","volume":"28","author":"PE Postmus","year":"2017","unstructured":"Postmus, P. E., Kerr, K. M., Oudkerk, M., Senan, S., Waller, D. A., Vansteenkiste, J., Escriu, C., Peters, S., Guidelines, E. S. M. O., & Committee. (2017). Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 28(suppl4), iv1-1iv21.","journal-title":"Annals of Oncology: Official Journal of the European Society for Medical Oncology"},{"key":"1143_CR4","doi-asserted-by":"publisher","first-page":"529","DOI":"10.2147\/OTT.S136579","volume":"11","author":"LY Wang","year":"2018","unstructured":"Wang, L. Y., Cui, J. J., Guo, A. X., & Yin, J. Y. (2018). Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients. OncoTargets and Therapy, 11, 529\u2013538.","journal-title":"OncoTargets and Therapy"},{"issue":"24","key":"1143_CR5","doi-asserted-by":"publisher","first-page":"8195","DOI":"10.1074\/jbc.REV120.013433","volume":"295","author":"IM McDonald","year":"2020","unstructured":"McDonald, I. M., & Graves, L. M. (2020). Enigmatic MELK: The controversy surrounding its complex role in cancer. The Journal of Biological Chemistry, 295(24), 8195\u20138203.","journal-title":"The Journal of Biological Chemistry"},{"issue":"11","key":"1143_CR6","doi-asserted-by":"publisher","first-page":"21551","DOI":"10.3390\/ijms141121551","volume":"14","author":"P Jiang","year":"2013","unstructured":"Jiang, P., & Zhang, D. (2013). Maternal embryonic leucine zipper kinase (MELK): A novel regulator in cell cycle control, embryonic development, and cancer. International Journal of Molecular Sciences, 14(11), 21551\u201321560.","journal-title":"International Journal of Molecular Sciences"},{"issue":"Pt 6","key":"1143_CR7","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1242\/jcs.069567","volume":"124","author":"Y Le Page","year":"2011","unstructured":"Le Page, Y., Chartrain, I., Badouel, C., & Tassan, J. P. (2011). A functional analysis of MELK in cell division reveals a transition in the mode of cytokinesis during Xenopus development. Journal of Cell Science, 124(Pt 6), 958\u2013968.","journal-title":"Journal of Cell Science"},{"issue":"25","key":"1143_CR8","doi-asserted-by":"publisher","first-page":"20797","DOI":"10.1074\/jbc.M112.347757","volume":"287","author":"HA Seong","year":"2012","unstructured":"Seong, H. A., & Ha, H. (2012). Murine protein serine-threonine kinase 38 activates p53 function through Ser15 phosphorylation. The Journal of Biological Chemistry, 287(25), 20797\u201320810.","journal-title":"The Journal of Biological Chemistry"},{"issue":"2","key":"1143_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00109-012-0949-1","volume":"91","author":"R Kuner","year":"2013","unstructured":"Kuner, R., F\u00e4lth, M., Pressinotti, N. C., Brase, J. C., Puig, S. B., Metzger, J., Gade, S., Sch\u00e4fer, G., Bartsch, G., Steiner, E., Klocker, H., & S\u00fcltmann, H. (2013). The maternal embryonic leucine zipper kinase (MELK) is upregulated in high-grade prostate cancer. Journal of Molecular Medicine: Official Organ of the Gesellschaft Deutscher Naturforscher und \u00c4rzte, 91(2), 237\u2013248.","journal-title":"Journal of Molecular Medicine: Official Organ of the Gesellschaft Deutscher Naturforscher und \u00c4rzte"},{"key":"1143_CR10","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.2147\/OTT.S238958","volume":"13","author":"H Li","year":"2020","unstructured":"Li, H., Chen, M., Yang, Z., Wang, Q., Wang, J., Jin, D., Yang, X., Chen, F., Zhou, X., & Luo, K. (2020). Phillygenin, a MELK inhibitor, inhibits cell survival and epithelial-mesenchymal transition in pancreatic cancer cells. OncoTargets and Therapy, 13, 2833\u20132842.","journal-title":"OncoTargets and Therapy"},{"issue":"21","key":"1143_CR11","doi-asserted-by":"publisher","first-page":"9751","DOI":"10.1158\/0008-5472.CAN-04-4531","volume":"65","author":"D Gray","year":"2005","unstructured":"Gray, D., Jubb, A. M., Hogue, D., Dowd, P., Kljavin, N., Yi, S., Bai, W., Frantz, G., Zhang, Z., Koeppen, H., de Sauvage, F. J., & Davis, D. P. (2005). Maternal embryonic leucine zipper kinase\/murine protein serine-threonine kinase 38 is a promising therapeutic target for multiple cancers. Cancer Research, 65(21), 9751\u20139761.","journal-title":"Cancer Research"},{"issue":"9","key":"1143_CR12","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/14728222.2017.1363183","volume":"21","author":"MK Pitner","year":"2017","unstructured":"Pitner, M. K., Taliaferro, J. M., Dalby, K. N., & Bartholomeusz, C. (2017). MELK: A potential novel therapeutic target for TNBC and other aggressive malignancies. Expert Opinion on Therapeutic Targets, 21(9), 849\u2013859.","journal-title":"Expert Opinion on Therapeutic Targets"},{"issue":"12","key":"1143_CR13","doi-asserted-by":"publisher","first-page":"13621","DOI":"10.18632\/oncotarget.7297","volume":"7","author":"H Inoue","year":"2016","unstructured":"Inoue, H., Kato, T., Olugbile, S., Tamura, K., Chung, S., Miyamoto, T., Matsuo, Y., Salgia, R., Nakamura, Y., & Park, J. H. (2016). Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer. Oncotarget, 7(12), 13621\u201313633.","journal-title":"Oncotarget"},{"issue":"1","key":"1143_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/jnr.21471","volume":"86","author":"I Nakano","year":"2008","unstructured":"Nakano, I., Masterman-Smith, M., Saigusa, K., Paucar, A. A., Horvath, S., Shoemaker, L., Watanabe, M., Negro, A., Bajpai, R., Howes, A., Lelievre, V., Waschek, J. A., Lazareff, J. A., Freije, W. A., Liau, L. M., Gilbertson, R. J., Cloughesy, T. F., Geschwind, D. H., Nelson, S. F., \u2026 Kornblum, H. I. (2008). Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. Journal of Neuroscience Research, 86(1), 48\u201360.","journal-title":"Journal of Neuroscience Research"},{"issue":"24","key":"1143_CR15","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.21037\/atm-20-7520","volume":"8","author":"Z Jiao","year":"2020","unstructured":"Jiao, Z., Yu, A., He, X., Xuan, Y., Zhang, H., Wang, G., Shi, M., & Wang, T. (2020). Bioinformatics analysis to determine the prognostic value and prospective pathway signaling of miR-126 in non-small cell lung cancer. Annals of Translational Medicine, 8(24), 1639.","journal-title":"Annals of Translational Medicine"},{"key":"1143_CR16","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.8215","volume":"7","author":"L Zhang","year":"2019","unstructured":"Zhang, L., Peng, R., Sun, Y., Wang, J., Chong, X., & Zhang, Z. (2019). Identification of key genes in non-small cell lung cancer by bioinformatics analysis. PeerJ, 7, e8215.","journal-title":"PeerJ"},{"key":"1143_CR17","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.gene.2018.01.003","volume":"647","author":"J Piao","year":"2018","unstructured":"Piao, J., Sun, J., Yang, Y., Jin, T., Chen, L., & Lin, Z. (2018). Target gene screening and evaluation of prognostic values in non-small cell lung cancers by bioinformatics analysis. Gene, 647, 306\u2013311.","journal-title":"Gene"},{"issue":"16","key":"1143_CR18","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.2217\/bmm-2019-0052","volume":"13","author":"X Zang","year":"2019","unstructured":"Zang, X., Qian, C., Ruan, Y., Xie, J., Luo, T., Xu, B., & Jiang, J. (2019). Higher maternal embryonic leucine zipper kinase mRNA expression level is a poor prognostic factor in non-small-cell lung carcinoma patients. Biomarkers in Medicine, 13(16), 1349\u20131361.","journal-title":"Biomarkers in Medicine"},{"issue":"1","key":"1143_CR19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.chest.2016.10.010","volume":"151","author":"FC Detterbeck","year":"2017","unstructured":"Detterbeck, F. C., Boffa, D. J., Kim, A. W., & Tanoue, L. T. (2017). The eighth edition lung cancer stage classification. Chest, 151(1), 193\u2013203.","journal-title":"Chest"},{"issue":"24","key":"1143_CR20","doi-asserted-by":"publisher","first-page":"13790","DOI":"10.1073\/pnas.191502998","volume":"98","author":"A Bhattacharjee","year":"2001","unstructured":"Bhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., Loda, M., Weber, G., Mark, E. J., Lander, E. S., Wong, W., Johnson, B. E., Golub, T. R., Sugarbaker, D. J., & Meyerson, M. (2001). Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proceedings of the National Academy of Sciences of the United States of America, 98(24), 13790\u201313795.","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4","key":"1143_CR21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010312","volume":"5","author":"J Hou","year":"2010","unstructured":"Hou, J., Aerts, J., den Hamer, B., van Ijcken, W., den Bakker, M., Riegman, P., van der Leest, C., van der Spek, P., Foekens, J. A., Hoogsteden, H. C., Grosveld, F., & Philipsen, S. (2010). Gene expression-based classification of non-small cell lung carcinomas and survival prediction. PLoS ONE, 5(4), e10312.","journal-title":"PLoS ONE"},{"key":"1143_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3389\/fonc.2020.00453","volume":"10","author":"Z Zhang","year":"2020","unstructured":"Zhang, Z., Sun, C., Li, C., Jiao, X., Griffin, B. B., Dongol, S., Wu, H., Zhang, C., Cao, W., Dong, R., Yang, X., Zhang, Q., & Kong, B. (2020). Upregulated MELK leads to doxorubicin chemoresistance and M2 macrophage polarization via the miR-34a\/JAK2\/STAT3 pathway in uterine leiomyosarcoma. Frontiers in Oncology, 10, 453.","journal-title":"Frontiers in Oncology"},{"key":"1143_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.102609","volume":"51","author":"Q Xu","year":"2020","unstructured":"Xu, Q., Ge, Q., Zhou, Y., Yang, B., Yang, Q., Jiang, S., Jiang, R., Ai, Z., Zhang, Z., & Teng, Y. (2020). MELK promotes endometrial carcinoma progression via activating mTOR signaling pathway. eBioMedicine, 51, 102609.","journal-title":"eBioMedicine"},{"issue":"2","key":"1143_CR24","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1111\/jcmm.14878","volume":"24","author":"S Chen","year":"2020","unstructured":"Chen, S., Zhou, Q., Guo, Z., Wang, Y., Wang, L., Liu, X., Lu, M., Ju, L., Xiao, Y., & Wang, X. (2020). Inhibition of MELK produces potential anti-tumour effects in bladder cancer by inducing G1\/S cell cycle arrest via the ATM\/CHK2\/p53 pathway. Journal of Cellular and Molecular Medicine, 24(2), 1804\u20131821.","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"9","key":"1143_CR25","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.2174\/1871520620666200101141934","volume":"20","author":"JH Tian","year":"2020","unstructured":"Tian, J. H., Mu, L. J., Wang, M. Y., Zeng, J., Long, Q. Z., Guan, B., Wang, W., Jiang, Y. M., Bai, X. J., & Du, Y. F. (2020). BUB1B promotes proliferation of prostate cancer via transcriptional regulation of MELK. Anti-Cancer Agents in Medicinal Chemistry, 20(9), 1140\u20131146.","journal-title":"Anti-Cancer Agents in Medicinal Chemistry"},{"issue":"3","key":"1143_CR26","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1158\/1535-7163.MCT-18-0819","volume":"18","author":"A Chlenski","year":"2019","unstructured":"Chlenski, A., Park, C., Dobratic, M., Salwen, H. R., Budke, B., Park, J. H., Miller, R., Applebaum, M. A., Wilkinson, E., Nakamura, Y., Connell, P. P., & Cohn, S. L. (2019). Maternal embryonic leucine zipper kinase (MELK), a potential therapeutic target for neuroblastoma. Molecular Cancer Therapeutics, 18(3), 507\u2013516.","journal-title":"Molecular Cancer Therapeutics"},{"issue":"1","key":"1143_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/0963689719890860","volume":"28","author":"H Zhang","year":"2019","unstructured":"Zhang, H., Wei, P., Lv, W., Han, X., Yang, J., Qin, S., & Zhang, Y. (2019). MELK is upregulated in advanced clear cell renal cell carcinoma and promotes disease progression by phosphorylating PRAS40. Cell Transplantation, 28(1), 37\u201350.","journal-title":"Cell Transplantation"},{"issue":"4","key":"1143_CR28","first-page":"2540","volume":"41","author":"L Ren","year":"2019","unstructured":"Ren, L., Deng, B., Saloura, V., Park, J. H., & Nakamura, Y. (2019). MELK inhibition targets cancer stem cells through downregulation of SOX2 expression in head and neck cancer cells. Oncology Reports, 41(4), 2540\u20132548.","journal-title":"Oncology Reports"},{"issue":"1","key":"1143_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/medicina56010001","volume":"56","author":"A Cigliano","year":"2019","unstructured":"Cigliano, A., Pilo, M. G., Mela, M., Ribback, S., Dombrowski, F., Pes, G. M., Cossu, A., Evert, M., Calvisi, D. F., & Utpatel, K. (2019). Inhibition of MELK protooncogene as an innovative treatment for intrahepatic cholangiocarcinoma. Medicina, 56(1), 1.","journal-title":"Medicina"},{"issue":"2","key":"1143_CR30","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.18632\/oncotarget.23515","volume":"9","author":"S Guan","year":"2018","unstructured":"Guan, S., Lu, J., Zhao, Y., Yu, Y., Li, H., Chen, Z., Shi, Z., Liang, H., Wang, M., Guo, K., Chen, X., Sun, W., Bieerkehazhi, S., Xu, X., Sun, S., Agarwal, S., & Yang, J. (2018). MELK is a novel therapeutic target in high-risk neuroblastoma. Oncotarget, 9(2), 2591\u20132602.","journal-title":"Oncotarget"},{"issue":"6","key":"1143_CR31","first-page":"9934","volume":"15","author":"G Li","year":"2018","unstructured":"Li, G., Yang, M., Zuo, L., & Wang, M. X. (2018). MELK as a potential target to control cell proliferation in triple-negative breast cancer MDA-MB-231 cells. Oncology Letters, 15(6), 9934\u20139940.","journal-title":"Oncology Letters"},{"key":"1143_CR32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12935-018-0556-5","volume":"18","author":"Y Li","year":"2018","unstructured":"Li, Y., Li, Y., Chen, Y., Xie, Q., Dong, N., Gao, Y., Deng, H., Lu, C., & Wang, S. (2018). Correction to: MicroRNA-214-3p inhibits proliferation and cell cycle progression by targeting MELK in hepatocellular carcinoma and correlates cancer prognosis. Cancer Cell International, 18, 55.","journal-title":"Cancer Cell International"},{"issue":"10","key":"1143_CR33","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1016\/j.celrep.2017.11.033","volume":"21","author":"R Janostiak","year":"2017","unstructured":"Janostiak, R., Rauniyar, N., Lam, T. T., Ou, J., Zhu, L. J., Green, M. R., & Wajapeyee, N. (2017). MELK promotes melanoma growth by stimulating the NF-\u03baB pathway. Cell Reports, 21(10), 2829\u20132841.","journal-title":"Cell Reports"},{"issue":"12","key":"1143_CR34","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.18632\/oncotarget.790","volume":"3","author":"S Chung","year":"2012","unstructured":"Chung, S., Suzuki, H., Miyamoto, T., Takamatsu, N., Tatsuguchi, A., Ueda, K., Kijima, K., Nakamura, Y., & Matsuo, Y. (2012). Development of an orally-administrative MELK-targeting inhibitor that suppresses the growth of various types of human cancer. Oncotarget, 3(12), 1629\u20131640.","journal-title":"Oncotarget"},{"issue":"6","key":"1143_CR35","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/stem.1358","volume":"31","author":"K Joshi","year":"2013","unstructured":"Joshi, K., Banasavadi-Siddegowda, Y., Mo, X., Kim, S. H., Mao, P., Kig, C., Nardini, D., Sobol, R. W., Chow, L. M., Kornblum, H. I., Waclaw, R., Beullens, M., & Nakano, I. (2013). MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells, 31(6), 1051\u20131063.","journal-title":"Stem Cells"},{"issue":"11","key":"1143_CR36","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/nrm2510","volume":"9","author":"H Hochegger","year":"2008","unstructured":"Hochegger, H., Takeda, S., & Hunt, T. (2008). Cyclin-dependent kinases and cell-cycle transitions: Does one fit all. Nature Reviews Molecular Cell Biology, 9(11), 910\u2013916.","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"3","key":"1143_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc2602","volume":"9","author":"M Malumbres","year":"2009","unstructured":"Malumbres, M., & Barbacid, M. (2009). Cell cycle, CDKs and cancer: A changing paradigm. Nature Reviews Cancer, 9(3), 153\u2013166.","journal-title":"Nature Reviews Cancer"},{"issue":"8","key":"1143_CR38","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/nrc3090","volume":"11","author":"EA Musgrove","year":"2011","unstructured":"Musgrove, E. A., Caldon, C. E., Barraclough, J., Stone, A., & Sutherland, R. L. (2011). Cyclin D as a therapeutic target in cancer. Nature Reviews Cancer, 11(8), 558\u2013572.","journal-title":"Nature Reviews Cancer"},{"issue":"9","key":"1143_CR39","first-page":"2199","volume":"12","author":"HM Mahdey","year":"2011","unstructured":"Mahdey, H. M., Ramanathan, A., Ismail, S. M., Abraham, M. T., Jamaluddin, M., & Zain, R. B. (2011). Cyclin D1 amplification in tongue and cheek squamous cell carcinoma. Asian Pacific Journal of Cancer Prevention, 12(9), 2199\u20132204.","journal-title":"Asian Pacific Journal of Cancer Prevention"},{"issue":"5","key":"1143_CR40","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1128\/MCB.15.5.2612","volume":"15","author":"M Ohtsubo","year":"1995","unstructured":"Ohtsubo, M., Theodoras, A. M., Schumacher, J., Roberts, J. M., & Pagano, M. (1995). Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Molecular and Cellular Biology, 15(5), 2612\u20132624.","journal-title":"Molecular and Cellular Biology"},{"issue":"9","key":"1143_CR41","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1002\/jor.24659","volume":"38","author":"R Wei","year":"2020","unstructured":"Wei, R., Thanindratarn, P., Dean, D. C., Hornicek, F. J., Guo, W., & Duan, Z. (2020). Cyclin E1 is a prognostic biomarker and potential therapeutic target in osteosarcoma. Journal of Orthopaedic Research: Official Publication of the Orthopaedic Research Society, 38(9), 1952\u20131964.","journal-title":"Journal of Orthopaedic Research: Official Publication of the Orthopaedic Research Society"},{"issue":"14","key":"1143_CR42","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1200\/JCO.18.00925","volume":"37","author":"NC Turner","year":"2019","unstructured":"Turner, N. C., Liu, Y., Zhu, Z., Loi, S., Colleoni, M., Loibl, S., DeMichele, A., Harbeck, N., Andr\u00e9, F., Bayar, M. A., Michiels, S., Zhang, Z., Giorgetti, C., Arnedos, M., Huang Bartlett, C., & Cristofanilli, M. (2019). Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 37(14), 1169\u20131178.","journal-title":"Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology"},{"issue":"6","key":"1143_CR43","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.31557\/APJCP.2019.20.6.1667","volume":"20","author":"RD Yudhani","year":"2019","unstructured":"Yudhani, R. D., Astuti, I., Mustofa, M., Indarto, D., & Muthmainah, M. (2019). Metformin modulates cyclin D1 and P53 expression to inhibit cell proliferation and to induce apoptosis in cervical cancer cell lines. Asian Pacific Journal of Cancer Prevention, 20(6), 1667\u20131673.","journal-title":"Asian Pacific Journal of Cancer Prevention"}],"container-title":["Molecular Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12033-024-01143-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12033-024-01143-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12033-024-01143-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T06:45:57Z","timestamp":1742712357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12033-024-01143-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,27]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1143"],"URL":"https:\/\/doi.org\/10.1007\/s12033-024-01143-4","relation":{},"ISSN":["1073-6085","1559-0305"],"issn-type":[{"type":"print","value":"1073-6085"},{"type":"electronic","value":"1559-0305"}],"subject":[],"published":{"date-parts":[[2024,4,27]]},"assertion":[{"value":"17 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"These authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"The research received approval from the ethical committee of The Sixth People\u2019s Hospital of Nantong and Affiliated Hospital of Nantong University, Jiangsu, China with Approval No. NTLYLL2018103. The human research adhered to the latest version of the Declaration of Helsinki, and subjects provided informed permission prior to the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}